Adherium partners with Florida Lung, Asthma & Sleep Specialists to expand the Hailie platform into Central Florida
Adherium Limited (ASX: ADR) has announced a new partnership with Florida Lung, Asthma & Sleep Specialists (FLASS), a leading independent pulmonary and critical care practice in Central Florida. The announcement was dated 26 October 2026.
FLASS will implement the FDA-cleared Hailie platform across its network to enhance asthma and COPD management through remote therapeutic monitoring (RTM). The practice has several locations across the greater Orlando area, extending the platform’s US reach into a new region through an independent, physician-led group.
John Perry, Chief Executive Officer, Adherium
“FLASS is exactly the kind of partner we look for…”
Perry said the partnership “…extends the reach of the Hailie platform into Central Florida and continues our momentum in building the standard of digital respiratory care in the United States.”
When big ASX news breaks, our subscribers know first
What FLASS gets from the Hailie platform
FLASS was founded by Dr. Fortune Alabi, MD, and Dr. Fred Umeh, MD, more than a decade ago. It provides pulmonary medicine, critical care, asthma and sleep medicine services.
Beyond outpatient care, the practice has developed an expanding continuum of respiratory care that includes hospital-based services, post-acute care, rehabilitation facilities and in-home pulmonary rehabilitation.
With the Hailie platform, FLASS clinicians can integrate FDA-cleared Hailie sensors and remote monitoring services into clinical workflows, enabling:
- Real-time visibility into medication adherence and inhaler technique for patients with asthma and COPD
- Actionable insights that help clinicians personalise treatment and intervene proactively
- Early identification of patients at risk of exacerbations, supporting timely outreach before breathing attacks occur
- Ongoing patient engagement between office visits through reimbursable remote therapeutic monitoring
Dr. Fortune Alabi, Founder and Chief Executive Officer, FLASS
“Partnering with Adherium gives our clinicians real-time insight into how our patients are using their inhalers between visits. […] ultimately keep more of our asthma and COPD patients healthy and out of the hospital.”
How remote therapeutic monitoring works and why adherence matters
Medication adherence remains one of the greatest challenges in chronic respiratory care. Poor adherence and improper inhaler technique drive avoidable exacerbations (flare-ups of symptoms), emergency visits and hospitalisations.
Adherium’s own inhaler technique data from 265 monitored asthma patients showed that only 8.3% used their device with optimal technique, which underlines why objective monitoring between visits matters.
The Hailie platform attaches FDA-cleared sensors to patients’ existing inhalers, captures objective usage data, and delivers it to clinicians through an integrated monitoring workflow. That workflow supports reimbursement under established RTM codes.
For practices, reimbursable monitoring offers a financial basis for adopting the technology, which is relevant to how widely a platform like Hailie can be taken up.
Adherium’s RPM revenue growth earlier in 2026 shows how reimbursable monitoring translates into billable revenue, with two new CPT codes cutting the data threshold from 16 days to 2 days per month.
| Hailie feature | What it does | Clinical benefit |
|---|---|---|
| FDA-cleared sensors | Attach to patients’ existing inhalers and capture objective usage data | Real-time visibility into medication adherence and inhaler technique |
| Integrated monitoring workflow | Delivers usage data to clinicians | Actionable insights to personalise treatment and intervene proactively |
| Remote therapeutic monitoring | Supports reimbursement under established RTM codes | Ongoing patient engagement between office visits |
Rollout and Adherium’s growth in the US with the Hailie platform
The rollout will begin at FLASS locations across Central Florida. Adherium will provide implementation, clinical applications and patient onboarding support.
Adherium describes itself as a provider of integrated digital health solutions and a developer of connected respiratory medical devices, with more than 180,000 sold globally. The Hailie solution also includes mobile and desktop apps, plus Software Development Kit (SDK) and Application Programming Interface (API) integration tools.
Perry referred to “…the strong results our partners are seeing across the country…” as the backdrop to the partnership. For investors, the addition of another independent US practice adds to Adherium’s commercial footprint in the region.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors getting FREE breaking ASX news from Big News Blast within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button to receive healthcare and other non-resource alerts the moment market-moving announcements land, so you stay ahead of the market.